Gonadotropin-releasing hormone agonists: Strategies formanaging the hypoestrogenic effects of therapy
review
OA: closed
CC0
⤵ 9 in-corpus citations
AI-generated summary
This review discusses strategies for managing hypoestrogenic effects associated with gonadotropin-releasing hormone agonist therapy.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Gonadotropin-releasing hormone agonists have been shown to be comparable with danazol for the treatment of endometriosis. These results are important because danazol is associated with a significant number of side effects, particularly androgenic effects, such as weight gain and acne. Although gonadotropin-releasing hormone agonists are associated with hypoestrogenic side effects, such as hot flashes and reversible bone density loss, recent studies suggest that the risk of these side effects may be modified when gonadotropin-releasing hormone agonists are combined with a progestin. These findings suggest that such regimens may further enhance the clinical usefulness of gonadotropin-releasing hormone agonist therapy for endometriosis and other estrogen-mediated diseases.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (17)
- Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis via openalex
- GnRH Analogues in the Treatment of Endometriosis via openalex
- Hormonal effects of danazol and medical oophorectomy in endometriosis. via openalex
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? via openalex
- The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis via openalex
- The effects of combining norethindrone with a gonadotropin‐releasing hormone agonist in the treatment of symptomatic endometriosis via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. via openalex
- W91497135 via openalex
- W6717624033 via openalex
- W1531102169 via openalex
- W2129449855 via openalex
- W2287757320 via openalex
- W2416265216 via openalex
- W6603725897 via openalex
- W6607058909 via openalex
- W6714082336 via openalex
Cited by (9)
- Parietal endometriosis: case report 2015
- Nafarelin in the Treatment of Endometriosis 2010
- The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro 2001
- 10.1016/s0246-1064(19)30150-1 2000
- Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis 1997
- Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists 1997
- Excretion of urinary n-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss 1996
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. 1996
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment 1996
Source provenance
- europepmc
- last seen: 2026-08-03T06:10:56.557307+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:11:49.821429+00:00
- unpaywall
- last seen: 2026-08-03T06:41:53.707437+00:00
License: CC0
· commercial use OK